CD200R在肺鳞状细胞癌组织中的表达及其临床意义

  目的  探讨白细胞分化抗原CD200受体（CD200 receptor，CD200R）在肺鳞状细胞癌（lung squamous cell carcinoma，LSCC）组织中的表达及其临床意义。  方法  选取2004年1月至2011年12月100例于天津医科大学肿瘤医院行手术切除的LSCC患者组织标本，应用免疫组织化学法检测CD200R的表达，体外细胞实验验证CD200R对细胞增殖的作用。  结果  CD200R主要在LSCC组织的细胞质和细胞膜表达，55%（55/100）呈高表达，45%（45/100）呈低表达。高表达患者的总生存（overall survival，OS）期和无病生存（disease free survial，DFS）期分别为46个月和32个月，均低于低表达患者（P=0.020，P=0.001）。CD200R是患者预后的独立影响因素（P＜0.05）。CD200R表达降低后细胞生长和克隆形成能力降低。  结论  LSCC患者组织中存在CD200R表达，且其高表达与患者的不良预后相关。敲低CD200R后细胞的生长增殖能力降低，CD200R可作为预测LSCC复发和生存的新型标志物，为肿瘤治疗技术开发提供新的依据。 

CD200R expression and its clinical significance in lung squamous cell carcinoma

  Objective  To investigate the expression and clinical significance of the leukocyte differentiation antigen CD200 receptor (CD200R) in lung squamous cell carcinoma (LSCC).  Methods  LSCC specimens were collected from 100 patients who were enrolled in the study and underwent surgical resection from January 2004 to December 2011 at Tianjin Medical University Cancer Institute and Hospital. CD200R expression was detected by immunohistochemistry, and the effect of CD200R expression on cell proliferation and colony formation capacity was determined by in vitro cellular assays.  Results  CD200R was found to be mainly expressed in the cytoplasm and cell membrane, with 55% (55/100) of the patient specimens exhibiting high expression and 45% (45/100) showing low expression of CD200R. The overall survival (OS) and disease free survival (DFS) of the patients with high CD200R expression were 46 months and 32 months, respectively, and were significantly shorter than those of patients with low CD200R expression (P=0.020 for OS and P=0.001 for DFS). CD200R was an independent prognostic factor for the patients (P < 0.05). The in vitro cellular assays showed that the proliferation and colony forming capacity of the LSCC cells were significantly decreased after knocking down CD200R expression.  Conclusions  High expression of CD200R in LSCC tissues is associated with poor prognosis. CD200R knockdown inhibits LSCC cell proliferation. Thus, CD200R can be used as a new biomarker to predict the recurrence and survival of LSCC, as well as a therapeutic target for LSCC.